This series of Annals of Translational Medicine introduces a collection of review articles on the full spectrum of heart failure (HF), given the tremendous growth that the field has experienced over the recent years. The crucial role of guideline directed medical therapy (GDMT) instituted at the primary care level is along with the role of advanced therapies for refractory cases, as both are interconnected and are two poles of a continuum.
Editorial on Heart Failure Update and Advances in 2021
Editorial for “Heart Failure Update and Advances in 2021”
Review Article on Heart Failure Update and Advances in 2021
Updates in pharmacotherapy of heart failure with reduced ejection fraction
Optimal diuretic strategies in heart failure
Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
Narrative review of pharmacotherapy for transthyretin cardiac amyloid
Management of left ventricular thrombus: a narrative review
Antiplatelet and anticoagulation strategies for left ventricular assist devices
Pulmonary vasodilator use in continuous-flow left ventricular assist device management
Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction
Disclosure:
The series “Heart Failure Update and Advances in 2021” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Debabrata Mukherjee and Jose Benjamin Cruz Rodriguez served as the unpaid Guest Editors for the series.